Antabio SAS advances cystic fibrosis programme
Antabio SAS has got a US-$4.4m tranche from CARB-X to advance preclinical development of its P. aeruginosa treatment in Cystic Fibrosis patients
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1165 entries already.
Entries by Thomas Gabrielczyk
Hydrogel fights wound infection and inflammation
/in News/by Thomas GabrielczykSwedish and Danish researchers have created a hydrogel that kills various types of bacteria and reduces inflammation in mice and pigs with infected wounds.
Merry Christmas and a Happy New Year
/in News/by Thomas GabrielczykEuropean Biotechnology Magazine will be back with breaking news and backgrounds on 2 January. Best wishes
British diagnostics play OBD lands contract with US pharma
/in News/by Thomas GabrielczykThe technology of Oxford-based Oxford Biodynamics (OBD) promises insights into why immunotherapies only work in some patients but not in all. A major US pharma company now wants to validate […]
Truffle’s BioMedTech fund filled with 250m
/in News/by Thomas GabrielczykParis-based European venture capital company Truffle Capital closed its 250m BioMedTech fund celebrating its company building approach.
Biomarker identifies residual congestion in heart failure patients
/in News/by Thomas GabrielczykData from 1,200 heart failure patients demonstrate that high discharge levels of the biomarker bio-ADM® (bioactive Adrenomedullin) indicate residual congestion in heart failure patients.
Belgian start-up takes fight on neuropathies
/in News/by Thomas GabrielczykThe new company, named Augustine Therapeutics, is a Vlaams Instituut voor Biotechnologie (VIB) and Katholieke Universiteit (KU) Leuven spin-off. Funded with 4.2m from mainly local investors, Augustine’s first priority is finding […]
Second clinical failure of Transgene in 2019
/in News/by Thomas GabrielczykFrench Transgene SA said it has terminated its lead programme TG4010 in combination with chemotherapy and checkpoint inhibition.
Microbiota contribute to skin damage in cancer therapy
/in News/by Thomas GabrielczykNew research demonstrates that disruption of EGF receptor signalling allows commensal bacteria to invade hairs and cause skin lesions.
BIOncoTech Therapeutics and MSD combine cancer drugs
/in News/by Thomas GabrielczykMadrid-based RNA specialist Bioncotech Therapeutics has entered into a Phase II clinical trial collaboration with a MSD subsidiary.